Bioventus Announces CEO Leadership Change
DURHAM, N.C., April 05, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
Month: April 2023
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
– Investor call to be held at 9:00 a.m. ET on April 18, 2023 –…
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
– Investor call to be held at 9:00 a.m. ET on April 18, 2023 –…
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company…
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company…
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasis ZORYVE…
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasis ZORYVE…
Fulcrum Therapeutics Announces CFO Resignation
Rajavelu to continue supporting Fulcrum in a consulting capacity CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE)…
Fulcrum Therapeutics Announces CFO Resignation
Rajavelu to continue supporting Fulcrum in a consulting capacity CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE)…
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB…
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB…
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
U.S. sales of Macrilen®for adult use to be temporarily discontinued as of May 23, 2023,…
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
U.S. sales of Macrilen®for adult use to be temporarily discontinued as of May 23, 2023,…
Syneos Health Wins 2023 ViE Award
Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) —…
Syneos Health Wins 2023 ViE Award
Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) —…
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up…
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up…
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…